Hematologic Cancers News
Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
Evidence from previous studies have demonstrated that combined modality therapy with chemotherapy and radiotherapy may improve long-term outcomes in this patient population.
2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia
Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.
Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML
Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.
Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Rituximab Plus Lenalidomide As First-Line Treatment May Be Effective in Follicular Lymphoma
Researchers randomly assigned 1030 patients with grade 1 to 3a follicular lymphoma to receive lenalidomide plus rituximab or rituximab plus investigator's choice chemotherapy of CHOP, CVP, or bendamustine.
Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia
Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.
In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia
The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.
Small Study Shows Curative Benefit of Allogeneic Hematopoietic Cell Transplantation Mantle Cell Lymphoma
Moffitt Cancer Center investigators believe allo-HCT may actually be "curative" for patients with a certain type of lymphoma.
Rituximab in Frontline Therapy May Reduce the Risk of Transformation in Follicular Lymphoma
The introduction of rituximab has greatly improved outcomes among patients with follicular lymphoma, but its impact on the risk of transformation and post-transformation are unclear.
For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More
Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.
Ibrutinib May Be Effective as First-Line Agent in Treatment of Waldenström's Macroglobulinemia
The effectiveness of ibrutinib in the frontline setting has not been definitively established.
Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
The efficacy of rituximab plus prednisolone had not been evaluated prior to the current study.
R-THP-COP a New Therapeutic Alternative for Diffuse Large B-Cell Lymphoma
Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.
JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas
While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.
Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia
CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.
Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma
In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly
Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenström Macroglobulinemia
Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.
Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma
Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma
- First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials